Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Jakesz, R; Greil, R; Gnant, M; Schmid, M; Kwasny, W; Kubista, E; Mineritsch, B; Tausch, C; Stierer, M; Hofbauer, F; Renner, K; Dadak, C; Ruecklinger, E; Samonigg, H.
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
J Natl Cancer Inst. 2007; 99(24):1845-1853
Doi: 10.1093/jnci/djm246
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Samonigg Hellmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Clinical trial data have shown that among breast cancer patients who were disease free after 5 years of adjuvant treatment with tamoxifen, further extended treatment with the nonsteroidal aromatase inhibitor letrozole reduces breast cancer recurrence. We examined the efficacy and tolerability of extended adjuvant therapy with another aromatase inhibitor, anastrozole, for 3 years among women who had completed 5 years of adjuvant therapy. METHODS: Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6a is an extension of ABCSG Trial 6, in which hormone receptor-positive postmenopausal patients received 5 years of adjuvant tamoxifen, with or without the aromatase inhibitor aminoglutethimide, for the first 2 years of therapy. For ABCSG Trial 6a, patients who were disease free at the end of Trial 6 were randomly assigned to receive either 3 years of anastrozole or no further treatment. Efficacy data were analyzed with the use of a Cox proportional hazards regression model with two-sided P values and Kaplan-Meier curves, and tolerability data were estimated using logistic regression analysis with odds ratios and 95% confidence intervals (CIs). RESULTS: ABCSG Trial 6a included 856 patients. At a median follow-up of 62.3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0.62; 95% CI = 0.40 to 0.96, P = .031). Anastrozole was well tolerated, and no unexpected adverse events were reported. CONCLUSIONS: These data confirm the benefit of extending adjuvant tamoxifen therapy beyond 5 years with anastrozole compared with no further treatment. Further research is required to define the optimum length of extended adjuvant therapy and to investigate the possibility of tailoring this period to suit different disease types.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Aminoglutethimide - therapeutic use
- Antineoplastic Agents, Hormonal - administration and dosage
- Aromatase Inhibitors - administration and dosage
- Austria - administration and dosage
- Breast Neoplasms - chemistry
- Chemotherapy, Adjuvant - chemistry
- Disease-Free Survival - chemistry
- Drug Administration Schedule - chemistry
- Female - chemistry
- Humans - chemistry
- Kaplan-Meiers Estimate - chemistry
- Logistic Models - chemistry
- Lymphatic Metastasis - chemistry
- Male - chemistry
- Middle Aged - chemistry
- Nitriles - administration and dosage
- Odds Ratio - administration and dosage
- Postmenopause - administration and dosage
- Proportional Hazards Models - administration and dosage
- Prospective Studies - administration and dosage
- Receptors, Estrogen - analysis
- Receptors, Progesterone - analysis
- Research Design - analysis
- Tamoxifen - therapeutic use
- Treatment Outcome - therapeutic use
- Triazoles - administration and dosage